Clinical Review

Venous Thromboembolism


 

Venous thromboembolism (VTE) and its associated complications account for significant morbidity and mortality. Each year between 100 and 180 persons per 100,000 develop a VTE in the Western countries. The majority of VTEs are classified as either pulmonary embolism (PE), which accounts for one third of the events, or deep vein thrombosis (DVT), which is responsible for the remaining two thirds. Between 20% and 30% of patients diagnosed with thrombotic events will die within the first month after diagnosis. PE is a common consequence of DVT; 40% of patients who are diagnosed with a DVT will be subsequently found to have a PE upon further imaging. The high rate of association is also seen in those who present with a PE, 70% of whom will also be found to have a concomitant DVT.

To read the full article in PDF:

Click here

Recommended Reading

AMPLIFY: Apixaban beat warfarin on safety in acute VTE
MDedge Hematology and Oncology
FDA again rejects rivaroxaban for ACS
MDedge Hematology and Oncology
Dabigatran noninferior to warfarin for preventing recurrent VTE
MDedge Hematology and Oncology
Fusion protein controls surgery-related bleeding in hemophilia B
MDedge Hematology and Oncology
CDC finds cluster of newborns with late VKDB
MDedge Hematology and Oncology
New drug stacks up well against warfarin
MDedge Hematology and Oncology
New antiplatelet drug seems more effective than standard
MDedge Hematology and Oncology
Fraud, errors were behind delay of apixaban approval, report shows
MDedge Hematology and Oncology
Factor can prevent bleeding in hemophilia A
MDedge Hematology and Oncology
New antihemophilic factors last longer than standard treatments
MDedge Hematology and Oncology